PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27050801-0 2016 Impact of the Arg 16 allele of the B2AR gene on the effect of withdrawal of LABA in patients with moderate to severe asthma. LABA 76-80 adrenoceptor beta 2 Homo sapiens 35-39 27452453-2 2016 A long-acting muscarinic receptor antagonist (LAMA) added to an inhaled corticosteroid (ICS)/long-acting beta2-adrenoceptor agonist (LABA) fixed-dose combination (FDC) can improve efficacy of pharmacological treatment of patients with chronic obstructive pulmonary disease (COPD). LABA 133-137 adrenoceptor beta 2 Homo sapiens 105-123 27050801-8 2016 CONCLUSIONS: Withdrawal of LABA therapy in asthmatics with the Arg/Arg genotype at the 16th amino acid position of B2AR did not lead to significant improvement in AM PEFR. LABA 27-31 adrenoceptor beta 2 Homo sapiens 115-119 27582089-1 2016 BACKGROUND: Vilanterol (VI) is a long-acting beta2-agonist (LABA) that binds to the beta2-adrenoceptor on the airway smooth muscle, producing bronchodilation. LABA 60-64 adrenoceptor beta 2 Homo sapiens 84-102 26676161-1 2015 Olodaterol (BI 1744 CL) is a novel, once-daily long-acting beta2-agonist (LABA) designed with the aim of improving beta2-adrenoreceptor selectivity and intrinsic activity. LABA 74-78 adrenoceptor beta 2 Homo sapiens 115-135 24641588-1 2014 Beta2 (beta2) adrenergic receptor agonists (beta agonists) are a commonly prescribed treatment for asthma despite the small increase in risk for life-threatening adverse responses associated with long-acting beta agonist (LABA). LABA 222-226 adrenoceptor beta 2 Homo sapiens 7-33 25377687-1 2015 Fixed dose combination (FDC) dual bronchodilators that co-administer a long acting beta2 -adrenoceptor agonist (LABA) and a long acting muscarinic antagonist (LAMA) are a new class of inhaled treatment for chronic obstructive pulmonary disease (COPD). LABA 112-116 adrenoceptor beta 2 Homo sapiens 83-102 18023995-1 2008 Formoterol is a selective long-acting beta2-adrenergic receptor agonist (LABA) that provides significant and sustained bronchodilatory effect for up to 12h following a single dose. LABA 73-77 adrenoceptor beta 2 Homo sapiens 38-63 24621682-3 2014 The beta2-adrenergic receptor gene (ADRB2) contains a common, non-synonymous single nucleotide polymorphism, Gly16Arg, that is unlikely to account for the rare, life-threatening events seen with LABA use. LABA 195-199 adrenoceptor beta 2 Homo sapiens 36-41 24621682-4 2014 We hypothesise that rare ADRB2 variants modulate therapeutic responses to LABA therapy and contribute to rare, severe adverse events. LABA 74-78 adrenoceptor beta 2 Homo sapiens 25-30 24621682-14 2014 INTERPRETATION: The rare ADRB2 variants Ile164 and -376ins are associated with adverse events during LABA therapy and should be evaluated in large clinical trials including the current FDA-mandated safety study. LABA 101-105 adrenoceptor beta 2 Homo sapiens 25-30 24279851-1 2013 BACKGROUND: Current evidence suggests that asthma patients with the ADRB2 Arg16 genotype have a poorer response to long-acting beta2-agonists (LABA), but the results remain inconsistent. LABA 143-147 adrenoceptor beta 2 Homo sapiens 68-73 24279851-7 2013 CONCLUSION: Children who are homozygous for ADRB2 Arg16 have an increased risk of exacerbations when treated with combined LABA and ICS. LABA 123-127 adrenoceptor beta 2 Homo sapiens 44-49 18666664-6 2008 A combination of ICS with long-acting beta-2-adrenoceptor agonists (LABA) is prescribed in patients with GOLD stage III-IV with at least 2 exacerbations in the past year, a deterioration of the quality of life and with symptoms, if treatment with a LABA alone or an ICS alone results in insufficient improvement. LABA 68-72 adrenoceptor beta 2 Homo sapiens 38-57 22526864-2 2012 We sought to determine whether haplotypic variation of the beta2AR affects the functional outcomes of long-acting beta2-agonist (LABA) treatment for chronic obstructive pulmonary disease (COPD) when used as monotherapy. LABA 129-133 adrenoceptor beta 2 Homo sapiens 59-66 22526864-8 2012 CONCLUSIONS: Homozygous haplotype for the CysGlyGln of beta2AR may be associated with susceptibility to desensitization to LABA in patients with COPD. LABA 123-127 adrenoceptor beta 2 Homo sapiens 55-62 19430548-2 2009 This study evaluated the effect of the beta2-adrenergic receptor (ADRB2) polymorphism on lung function and asthma control with regular use of combination treatment of an inhaled ICS plus LABA. LABA 187-191 adrenoceptor beta 2 Homo sapiens 39-64 19430548-2 2009 This study evaluated the effect of the beta2-adrenergic receptor (ADRB2) polymorphism on lung function and asthma control with regular use of combination treatment of an inhaled ICS plus LABA. LABA 187-191 adrenoceptor beta 2 Homo sapiens 66-71 18071293-1 2008 There is unequivocal evidence that the combination of an inhaled corticosteroid (ICS) -- i.e. glucocorticoid -- and an inhaled long-acting beta(2)-adrenoceptor agonist (LABA) is superior to each component administered as a monotherapy alone in the clinical management of asthma. LABA 169-173 adrenoceptor beta 2 Homo sapiens 139-159 33622325-4 2021 OBJECTIVE: We hypothesize that the LABA olodaterol can inhibit airway inflammation resulting from exposure to respiratory syncytial virus (RSV) via its binding receptor, the beta2-adrenergic receptor. LABA 35-39 adrenoceptor beta 2 Homo sapiens 174-199 17901197-1 2008 Addition of an inhaled long-acting beta(2)-adrenoceptor agonist (LABA) to an inhaled corticosteroid (ICS) is more effective at improving asthma control and reducing exacerbations than increasing the dose of ICS. LABA 65-69 adrenoceptor beta 2 Homo sapiens 35-55 14668964-1 2004 BACKGROUND: Predisposition to subsensitivity with long-acting beta(2)-agonists (LABA) or regular short-acting beta(2)-agonists (SABA) is related to polymorphisms at codon 16 of the beta(2)-adrenoceptor. LABA 80-84 adrenoceptor beta 2 Homo sapiens 181-201 34128573-3 2021 OBJECTIVE: We assessed whether the haplotype analysis could explain the association between the polymorphisms at codons 16 (Arg16Gly) and 27 (Gln27Glu) in ADRB2 and risk of asthma exacerbations in patients treated with inhaled corticosteroids (ICS) plus LABA. LABA 254-258 adrenoceptor beta 2 Homo sapiens 155-160 34128573-10 2021 CONCLUSION AND CLINICAL RELEVANCE: The ADRB2 Arg16 haplotype, presumably mainly driven by the Arg16, increased the risk of asthma exacerbations in patients treated with ICS plus LABA. LABA 178-182 adrenoceptor beta 2 Homo sapiens 39-44 16872239-4 2006 In these symptomatic asthmatic patients, guidelines advocate the initiation of a long-acting beta2-adrenoceptor agonist (LABA) as additional second-line controller therapy. LABA 121-125 adrenoceptor beta 2 Homo sapiens 93-111 14651722-1 2003 AIMS: Inhalers combining long acting beta2-adrenoceptor agonists (LABA) and corticosteroids (ICS) are indicated at Step 3 of current asthma guidelines. LABA 66-70 adrenoceptor beta 2 Homo sapiens 37-55 14524296-8 2003 Glucocoricosteroids may, in turn, regulate beta 2-adrenoceptor (beta 2 AR) function by increasing its expression, acting by restoring the ability of G-protein beta 2 AR coupling and inhibiting beta 2 AR down-regulation, thereby preventing desensitisation associated with long term LABA administration. LABA 281-285 adrenoceptor beta 2 Homo sapiens 43-62 14524296-8 2003 Glucocoricosteroids may, in turn, regulate beta 2-adrenoceptor (beta 2 AR) function by increasing its expression, acting by restoring the ability of G-protein beta 2 AR coupling and inhibiting beta 2 AR down-regulation, thereby preventing desensitisation associated with long term LABA administration. LABA 281-285 adrenoceptor beta 2 Homo sapiens 64-73 29992699-15 2018 CONCLUSIONS: ADRB2 rs1042713 variant is most consistently associated with response to LABA in children but not adults. LABA 86-90 adrenoceptor beta 2 Homo sapiens 13-18 30872116-10 2019 The after/before ICS plus LABA treatment ratio of B2AR number was 1.0 for alendronate (P = .86) and 0.8 for placebo (P = .15; P = .31 for difference between treatments). LABA 26-30 adrenoceptor beta 2 Homo sapiens 50-54 29650006-3 2018 Nevertheless, it is still uncertain whether adding a long-acting beta2-AR agonist (LABA) to an inhaled corticosteroid (ICS) results in an additive effect, or there is true synergy. LABA 83-87 adrenoceptor beta 2 Homo sapiens 65-73 29653961-2 2018 Operational model-fitting established that the long-acting beta2-adrenoceptor agonists (LABA) indacaterol, salmeterol, formoterol, and picumeterol were full agonists on BEAS-2B cells transfected with a cAMP-response element reporter but differed in efficacy (indacaterol >= formoterol > salmeterol >= picumeterol). LABA 88-92 adrenoceptor beta 2 Homo sapiens 59-77 30311516-2 2018 Olodaterol 5 microg, a long-acting beta2-adrenoceptor agonist (LABA) is one such bronchodilator indicated as a once-daily maintenance therapy. LABA 63-67 adrenoceptor beta 2 Homo sapiens 35-53 29115880-5 2018 One of the most promising genetic variants is the Arg16 variant in the ADRB2 gene to guide LABA treatment in asthmatic children. LABA 91-95 adrenoceptor beta 2 Homo sapiens 71-76 28987803-9 2018 LABA alone also suppressed TLR-induced IFN-alpha/beta expression, and the effect was reversed by the beta2-adrenoreceptor antagonist ICI118551. LABA 0-4 adrenoceptor beta 2 Homo sapiens 101-121